Mayra L Reyes

US Patent:

6783737, Aug 31, 2004

Filed:

Jan 25, 2002

Appl. No.:

10/057459

Inventors:

Joseph Nolfo - Hawthorne NJ
Victor W. Rosso - East Windsor NJ
Peter Lee - East Windsor NJ
Mayra B. Reyes - Monmouth Junction NJ
John J. Venit - North Brunswick NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

B01J 1200

US Classification:

422129, 130 99, 130100, 130102, 130103

Abstract:

Multiple parallel chemical reactions are performed under pressure in a reactor including a multi-row array of reaction vessels situated between a temperature control base and a fluid flow manifold. The manifold consists of an input portion connected to the fluid supply by a five-way valve and a distribution portion which includes separate parallel distribution channels, one for each row of reaction vessels. A control valve for each distribution channel is interposed between the manifold portions such that the fluid flow to each row of reaction vessels can be independently controlled. An explosion proof transparent shield can be situated between the base and manifold, surrounding the reaction vessels. The interior of the shield can be flooded with inert gas.

US Patent:

20080021044, Jan 24, 2008

Filed:

May 21, 2007

Appl. No.:

11/751155

Inventors:

Mitul Patel - Union NJ, US
Christopher Nilsen - Branchburg NJ, US
Mayra Reyes - Somerset NJ, US
Michael Humora - Cranbury NJ, US
Yun Qian - Doylestown PA, US
Fuqiang Liu - Lansdale PA, US
Xini Zhang - Bridgewater NJ, US
Kirk Sorgi - Doylestown PA, US

International Classification:

A61K 31/4965
A61P 7/02
C07D 241/08

US Classification:

514255060, 544408000

Abstract:

The present invention is directed to N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-s-oxo-1(2H)-pyrazineacetamide, pharmaceutical compositions containing said compound and methods of treatment comprising inhibiting a serine protease using said compound. The present invention is further directed to a process for the preparation of the N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide as a free base. The present invention is further directed to a process for the preparation of pharmaceutically acceptable salts of N-[2-[[(aminoiminomethyl)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide.